JPS63245696A - Method for measuring ceruloplasmin activity - Google Patents
Method for measuring ceruloplasmin activityInfo
- Publication number
- JPS63245696A JPS63245696A JP8051587A JP8051587A JPS63245696A JP S63245696 A JPS63245696 A JP S63245696A JP 8051587 A JP8051587 A JP 8051587A JP 8051587 A JP8051587 A JP 8051587A JP S63245696 A JPS63245696 A JP S63245696A
- Authority
- JP
- Japan
- Prior art keywords
- reagent
- ceruloplasmin
- concentration
- aminoantipyrine
- derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010075016 Ceruloplasmin Proteins 0.000 title claims abstract description 28
- 102100023321 Ceruloplasmin Human genes 0.000 title claims abstract description 28
- 230000000694 effects Effects 0.000 title claims abstract description 19
- 238000000034 method Methods 0.000 title claims description 27
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N 4-aminoantipyrine Chemical class CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 claims abstract description 17
- JYSUYJCLUODSLN-UHFFFAOYSA-N 1,3-benzothiazol-2-ylhydrazine Chemical compound C1=CC=C2SC(NN)=NC2=C1 JYSUYJCLUODSLN-UHFFFAOYSA-N 0.000 claims abstract description 7
- 125000002490 anilino group Chemical class [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims abstract 2
- -1 iron complex ions Chemical class 0.000 claims description 6
- 239000000872 buffer Substances 0.000 claims description 5
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 24
- 238000005259 measurement Methods 0.000 abstract description 7
- 239000012085 test solution Substances 0.000 abstract description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 abstract description 6
- 238000002835 absorbance Methods 0.000 abstract description 4
- 239000007853 buffer solution Substances 0.000 abstract description 4
- 150000002500 ions Chemical class 0.000 abstract description 4
- 229910052742 iron Inorganic materials 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 abstract description 3
- 206010029164 Nephrotic syndrome Diseases 0.000 abstract description 2
- 208000007502 anemia Diseases 0.000 abstract description 2
- 239000000243 solution Substances 0.000 abstract description 2
- 239000007836 KH2PO4 Substances 0.000 abstract 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 abstract 1
- 235000019796 monopotassium phosphate Nutrition 0.000 abstract 1
- 208000009928 nephrosis Diseases 0.000 abstract 1
- 231100001027 nephrosis Toxicity 0.000 abstract 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 239000012895 dilution Substances 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- CBCKQZAAMUWICA-UHFFFAOYSA-N 1,4-phenylenediamine Chemical compound NC1=CC=C(N)C=C1 CBCKQZAAMUWICA-UHFFFAOYSA-N 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000000691 measurement method Methods 0.000 description 4
- PHOLIFLKGONSGY-CSKARUKUSA-N (e)-(3-methyl-1,3-benzothiazol-2-ylidene)hydrazine Chemical compound C1=CC=C2S\C(=N\N)N(C)C2=C1 PHOLIFLKGONSGY-CSKARUKUSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 150000001448 anilines Chemical class 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- STBWJPWQQLXSCK-UHFFFAOYSA-N 3-(n-ethyl-3-methoxyanilino)propane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCN(CC)C1=CC=CC(OC)=C1 STBWJPWQQLXSCK-UHFFFAOYSA-N 0.000 description 2
- GIAVHGFPMPSIFI-UHFFFAOYSA-N 3-hydroxy-2,4,6-triiodobenzoic acid Chemical compound OC(=O)C1=C(I)C=C(I)C(O)=C1I GIAVHGFPMPSIFI-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 241001522296 Erithacus rubecula Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000004737 colorimetric analysis Methods 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- GGSUCNLOZRCGPQ-UHFFFAOYSA-N diethylaniline Chemical compound CCN(CC)C1=CC=CC=C1 GGSUCNLOZRCGPQ-UHFFFAOYSA-N 0.000 description 2
- 230000010438 iron metabolism Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229920002113 octoxynol Polymers 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- VRVSEBYMCSYYMF-UHFFFAOYSA-N (n,3-dimethylanilino)methanol Chemical compound OCN(C)C1=CC=CC(C)=C1 VRVSEBYMCSYYMF-UHFFFAOYSA-N 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- AGRSZBOCZMNJIN-UHFFFAOYSA-N 1-[n-(2-hydroxypropyl)-3-methylanilino]propan-2-ol Chemical compound CC(O)CN(CC(C)O)C1=CC=CC(C)=C1 AGRSZBOCZMNJIN-UHFFFAOYSA-N 0.000 description 1
- BZOMQFXAQDWKAP-UHFFFAOYSA-N 2-(3-methyl-n-propylanilino)ethanol Chemical compound CCCN(CCO)C1=CC=CC(C)=C1 BZOMQFXAQDWKAP-UHFFFAOYSA-N 0.000 description 1
- KRNUKKZDGDAWBF-UHFFFAOYSA-N 2-(n-ethyl-n-m-toluidino)ethanol Chemical compound OCCN(CC)C1=CC=CC(C)=C1 KRNUKKZDGDAWBF-UHFFFAOYSA-N 0.000 description 1
- HYVGFUIWHXLVNV-UHFFFAOYSA-N 2-(n-ethylanilino)ethanol Chemical compound OCCN(CC)C1=CC=CC=C1 HYVGFUIWHXLVNV-UHFFFAOYSA-N 0.000 description 1
- SCIPJHMVMRMZOW-UHFFFAOYSA-N 2-(n-methyl-3-propylanilino)ethanol Chemical compound CCCC1=CC=CC(N(C)CCO)=C1 SCIPJHMVMRMZOW-UHFFFAOYSA-N 0.000 description 1
- VIIZJXNVVJKISZ-UHFFFAOYSA-N 2-(n-methylanilino)ethanol Chemical compound OCCN(C)C1=CC=CC=C1 VIIZJXNVVJKISZ-UHFFFAOYSA-N 0.000 description 1
- VMNDRLYLEVCGAG-UHFFFAOYSA-N 2-[n-(2-hydroxyethyl)-3-methylanilino]ethanol Chemical compound CC1=CC=CC(N(CCO)CCO)=C1 VMNDRLYLEVCGAG-UHFFFAOYSA-N 0.000 description 1
- GIVVIAIOYXFANR-UHFFFAOYSA-N 3-(n,3-dimethylanilino)propan-1-ol Chemical compound OCCCN(C)C1=CC=CC(C)=C1 GIVVIAIOYXFANR-UHFFFAOYSA-N 0.000 description 1
- BTIDJAQNJLWPTI-UHFFFAOYSA-N 3-(n-ethyl-3,5-dimethoxyanilino)-2-hydroxypropane-1-sulfonic acid Chemical compound OS(=O)(=O)CC(O)CN(CC)C1=CC(OC)=CC(OC)=C1 BTIDJAQNJLWPTI-UHFFFAOYSA-N 0.000 description 1
- NZAVBNVWEPQSBL-UHFFFAOYSA-N 3-(n-ethyl-3,5-dimethoxyanilino)propane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCN(CC)C1=CC(OC)=CC(OC)=C1 NZAVBNVWEPQSBL-UHFFFAOYSA-N 0.000 description 1
- NPROGRQJOGOVDS-UHFFFAOYSA-N 3-(n-ethyl-3,5-dimethylanilino)propane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCN(CC)C1=CC(C)=CC(C)=C1 NPROGRQJOGOVDS-UHFFFAOYSA-N 0.000 description 1
- ZTQGWROHRVYSPW-UHFFFAOYSA-N 3-(n-ethyl-3-methylanilino)-2-hydroxypropane-1-sulfonic acid Chemical compound OS(=O)(=O)CC(O)CN(CC)C1=CC=CC(C)=C1 ZTQGWROHRVYSPW-UHFFFAOYSA-N 0.000 description 1
- OSLLNBXAVOQCHO-UHFFFAOYSA-N 3-(n-ethyl-3-methylanilino)propan-1-ol Chemical compound OCCCN(CC)C1=CC=CC(C)=C1 OSLLNBXAVOQCHO-UHFFFAOYSA-N 0.000 description 1
- LHZMSRLULDAWLM-UHFFFAOYSA-N 3-(n-ethylanilino)-2-hydroxypropane-1-sulfonic acid Chemical compound OS(=O)(=O)CC(O)CN(CC)C1=CC=CC=C1 LHZMSRLULDAWLM-UHFFFAOYSA-N 0.000 description 1
- GZFGOTFRPZRKDS-UHFFFAOYSA-N 4-bromophenol Chemical compound OC1=CC=C(Br)C=C1 GZFGOTFRPZRKDS-UHFFFAOYSA-N 0.000 description 1
- WXNZTHHGJRFXKQ-UHFFFAOYSA-N 4-chlorophenol Chemical compound OC1=CC=C(Cl)C=C1 WXNZTHHGJRFXKQ-UHFFFAOYSA-N 0.000 description 1
- 108010068307 Alpha-Globulins Proteins 0.000 description 1
- 102000002572 Alpha-Globulins Human genes 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000018839 Wilson disease Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- YAGKRVSRTSUGEY-UHFFFAOYSA-N ferricyanide Chemical compound [Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] YAGKRVSRTSUGEY-UHFFFAOYSA-N 0.000 description 1
- 208000020694 gallbladder disease Diseases 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- CWOMTHDOJCARBY-UHFFFAOYSA-N n,n,3-trimethylaniline Chemical compound CN(C)C1=CC=CC(C)=C1 CWOMTHDOJCARBY-UHFFFAOYSA-N 0.000 description 1
- OVSARSKQWCLSJT-UHFFFAOYSA-N n,n-di(propan-2-yl)aniline Chemical compound CC(C)N(C(C)C)C1=CC=CC=C1 OVSARSKQWCLSJT-UHFFFAOYSA-N 0.000 description 1
- CIPVVROJHKLHJI-UHFFFAOYSA-N n,n-diethyl-3-methylaniline Chemical compound CCN(CC)C1=CC=CC(C)=C1 CIPVVROJHKLHJI-UHFFFAOYSA-N 0.000 description 1
- ZPEDSBOBSNNATM-UHFFFAOYSA-N n-[2-(n-ethyl-3-methylanilino)ethyl]acetamide Chemical compound CC(=O)NCCN(CC)C1=CC=CC(C)=C1 ZPEDSBOBSNNATM-UHFFFAOYSA-N 0.000 description 1
- REBPIUGTTRIAEO-UHFFFAOYSA-N n-[2-(n-ethyl-3-methylanilino)ethyl]methanesulfonamide Chemical compound CS(=O)(=O)NCCN(CC)C1=CC=CC(C)=C1 REBPIUGTTRIAEO-UHFFFAOYSA-N 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Inorganic materials [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 150000004992 toluidines Chemical class 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
Abstract
Description
【発明の詳細な説明】
[産業上の利用分野]
本発明は、セルロプラスミン活性を正確且つ迅速に測定
する方法に関するものである。DETAILED DESCRIPTION OF THE INVENTION [Industrial Field of Application] The present invention relates to a method for accurately and rapidly measuring ceruloplasmin activity.
[従来の技術]
哺乳類の血液中に存在するセルロプラスミンは、電気泳
動的にはα−グロブリン画分に含まれる銅タンパク質で
ある。上記銅タンパク質は一般に鉄代謝と密接な関係を
持つと言われており、従ってセルロプラスミンの活性を
測定すれば、鉄代謝に関与する疾患例えばウィルソン氏
病、貧血、ネフローゼ症候群、胆嚢疾患及び妊娠等の診
断に有用な情報を得ることがでミ、臨床的意義が極めて
高いものである。[Prior Art] Ceruloplasmin present in mammalian blood is a copper protein contained in the α-globulin fraction electrophoretically. The copper protein mentioned above is generally said to have a close relationship with iron metabolism, and therefore, by measuring the activity of ceruloplasmin, diseases related to iron metabolism such as Wilson's disease, anemia, nephrotic syndrome, gallbladder disease, and pregnancy can be detected. Obtaining information useful for diagnosis is of extremely high clinical significance.
この様なセルロプラスミンを測定する方法は原理的に2
つに大別され、従来から免疫学的方法と化学的方法の2
通りが実施されている。In principle, there are two methods for measuring ceruloplasmin.
Traditionally, there are two methods: immunological methods and chemical methods.
Streets are being carried out.
これらの方法のうち、免疫学的測定法は、操作が繁雑で
分析に長時間を要し、また検出されるタンパク量は活性
・不活性の如何を問わないものであり、セルロプラスミ
ン活性の測定としては不正確な結果を与えるものであっ
た。Among these methods, the immunoassay method is complicated and requires a long time for analysis, and the amount of protein detected is independent of whether it is active or inactive, and it is difficult to measure ceruloplasmin activity. This gave inaccurate results.
一方化学的測定としては、その代表例としてロビン(R
ovin)の比色法がある。この方法はp−フェニレン
ジアミンを用いてオキシダーゼ活性を染色測定する方法
である。この方法においても分析に30分以上の時間を
必要とし、しかも別途検体ブランクについての測定結果
を求める必要があり、手間を要するものであった。又こ
の方法で用いられる試薬(一般にp−フェニレンジアミ
ンを酢酸lI街液に溶解したもの)は不安定で分析する
たび毎に調製する必要があるばかりか、前記p −フェ
ニレンジアミンは労働安全衛生上も極めて不都合な物質
とされている。従ってこの方法も、日常検査法としては
十分と言えない。On the other hand, as a typical example of chemical measurement, Robin (R
ovin) colorimetric method. This method uses p-phenylenediamine to stain and measure oxidase activity. This method also requires more than 30 minutes for analysis, and it is also necessary to obtain measurement results for a sample blank separately, which is time-consuming. Furthermore, the reagent used in this method (generally p-phenylenediamine dissolved in lI acetic acid solution) is not only unstable and must be prepared for each analysis, but also the p-phenylenediamine has safety and health concerns. is also considered to be an extremely inconvenient substance. Therefore, this method cannot be considered sufficient as a routine testing method either.
上記ロビンの比色法が持つ欠点を改良するものとして、
例えば特開昭57−68797号に示された様な技術が
既に提案されている。この方法は4−アミノアンチピリ
ン(又は3−メチル−2−ベンゾチアゾリノンヒドラゾ
ン)とN−置換アニリン化合物を基質としてセルロプラ
スミンを測定する方法であり、これらの物質を用いるこ
とによってロビン法におけるp−フェニレンジアミンに
基づく欠点を解消したものである。To improve the drawbacks of Robin's colorimetric method,
For example, a technique as shown in Japanese Patent Laid-Open No. 57-68797 has already been proposed. This method measures ceruloplasmin using 4-aminoantipyrine (or 3-methyl-2-benzothiazolinone hydrazone) and an N-substituted aniline compound as substrates, and by using these substances, p - It eliminates the drawbacks caused by phenylenediamine.
しかしながらこの方法は、p−フェニレンジアミンを用
いる場合に比べて感度の点で劣るという決定的な欠点を
有していた。However, this method had a decisive drawback in that it was inferior in sensitivity compared to the case of using p-phenylenediamine.
[発明が解決しようとする問題点]
本発明は上述した従来技術の欠点を解消する為になされ
たものであって、その目的とするところはセルロプラス
ミンの活性を迅速且つ正確に測定し得る方法を提供する
ことにある。[Problems to be Solved by the Invention] The present invention has been made to solve the above-mentioned drawbacks of the prior art, and its purpose is to provide a method that can quickly and accurately measure the activity of ceruloplasmin. Our goal is to provide the following.
[問題点を解決する為の手段]
本発明者らは上記目的を達成する為に種々検討し、更に
鋭意研究した結果、適当な反応条件を設定するならば、
セルロプラスミン活性を迅速且つ正確に定量分析できる
ことを見出し、蕊に本発明方法を完成したものである。[Means for Solving the Problems] In order to achieve the above object, the inventors of the present invention have made various considerations, and as a result of further intensive research, if appropriate reaction conditions are set,
We have discovered that ceruloplasmin activity can be quantitatively analyzed quickly and accurately, and have finally completed the method of the present invention.
即ち本発明方法は、4−アミノアンチピリン/アニリン
誘導体系、4−アミノアンチピリン/フェノール誘導体
系、
ベンゾチアゾリノンヒドラゾン誘導体/アニリン誘導体
系
よりなる群から選択されるいずれかの系を用いてセルロ
プラスミン活性を測定するに当たり、p H: 4.0
〜6.01
緩衝液の濃度: 0.02M〜0.2M4−アミノアン
チピリンの濃度:1〜20 a+M。That is, the method of the present invention uses any system selected from the group consisting of 4-aminoantipyrine/aniline derivative system, 4-aminoantipyrine/phenol derivative system, and benzothiazolinone hydrazone derivative/aniline derivative system to produce ceruloplasmin. When measuring activity, pH: 4.0
~6.01 Concentration of buffer: 0.02M ~0.2M Concentration of 4-aminoantipyrine: 1-20 a+M.
ベンゾチアゾリノンヒドラゾン誘導体の濃度=0.1〜
2mM
の各条件を満足する様に調整した反応系中に2価鉄の錯
イオンが1μM以上含まれた状態でセルロプラスミンを
測定する点に要旨を有するセルロプラスミン活性の測定
方法である。Concentration of benzothiazolinone hydrazone derivative = 0.1~
This is a method for measuring ceruloplasmin activity, the gist of which is to measure ceruloplasmin in a reaction system that has been adjusted to satisfy each condition of 2mM and contains 1 μM or more of divalent iron complex ions.
[作用]
本発明で用いられるアニリン誘導体の具体例としては、
N−メチル−N−ヒドロキシメチル−3−メチルアニリ
ン、N−エチル−N−ヒドロキシエチル−3−メチルア
ニリン、N−エチル−N−ヒドロキシエチル−3−二チ
ルアニリン、N−メチル−N−とドロキシエチル−3−
メチルアニリン、N−メチル−N−ヒドロキシプロピル
−3−メチルアニリン、N−エチル−N−ヒドロキシプ
ロピル−3−メチルアニリン、N−メチル−N−ヒドロ
キシエチル−3−二チルアニリン、N−プロピル−N−
ヒドロキシエチル−3−メチルアニリン、N−メチル−
N−ヒドロキシエチル−3−プロピルアニリン、N、N
−ビス(β−ヒドロキシエチル)−3−メチルアニリン
、N、 N−ビス(β−ヒドロキシプロピル)−3−メ
チルアニリン、N、N−ジメチル−3−メチルアニリン
、N、N−ジメチル−3−二チルアニリン、N、N−ジ
メチル−3−プロとルアニリン、N、N−ジエチル−3
−メチルアニリン、”N、 N−ジエチル−3−二チル
アニリン、N、N−ジプロピル−3−メチルアニリン、
N−エチル−N−(β−メタンスルホンアミドエチル)
−m−トルイジン、N−エチル−N−(β−アセトアミ
ドエチル)−3−メチルアニリン、N、N−ジメチルア
ニリン、N、N−ジエチルアニリン、N、N−ジイソプ
ロピルアニリン、N−メチル−N−ヒドロキシエチルア
ニリン、N−エチル−N−ヒドロキシエチルアニリン、
N−エチル−N−スルホプロピル−m−)−ルイジン、
N−エチル−N−(2−ヒドロキシ−3−スルホプロピ
ル)−m−トルイジン、N−エチル−N−(2−ビトロ
キシ−3−スルホプロピル)−m−アニシジン、N−エ
チル−N−(2−ヒドロキシ−3−スルホプロピル)ア
ニリン、3.5−ジメトキシ−N−エチル−N−(2−
ハイドロキシ−3−スルホプロピル)アニリン、3.5
−ジメチル−N−エチル−N−(2−ヒドロキシ−3−
スルホプロピル)アニリン、N−エチル−N−スルホプ
ロピル−m−アニシジン、N−エチル−N−スルホプロ
ピル−3,5−ジメチルアニリン、N−エチル−N−ス
ルホプロピル−3,5−ジメトキシアニリン等が挙げら
れる。[Action] Specific examples of the aniline derivatives used in the present invention include:
N-Methyl-N-hydroxymethyl-3-methylaniline, N-ethyl-N-hydroxyethyl-3-methylaniline, N-ethyl-N-hydroxyethyl-3-ditylaniline, N-methyl-N- and droxyethyl -3-
Methylaniline, N-methyl-N-hydroxypropyl-3-methylaniline, N-ethyl-N-hydroxypropyl-3-methylaniline, N-methyl-N-hydroxyethyl-3-ditylaniline, N-propyl-N −
Hydroxyethyl-3-methylaniline, N-methyl-
N-hydroxyethyl-3-propylaniline, N,N
-bis(β-hydroxyethyl)-3-methylaniline, N,N-bis(β-hydroxypropyl)-3-methylaniline, N,N-dimethyl-3-methylaniline, N,N-dimethyl-3- Dithylaniline, N,N-dimethyl-3-pro and luaniline, N,N-diethyl-3
- methylaniline, "N, N-diethyl-3-ditylaniline, N, N-dipropyl-3-methylaniline,"
N-ethyl-N-(β-methanesulfonamidoethyl)
-m-Toluidine, N-ethyl-N-(β-acetamidoethyl)-3-methylaniline, N,N-dimethylaniline, N,N-diethylaniline, N,N-diisopropylaniline, N-methyl-N- Hydroxyethylaniline, N-ethyl-N-hydroxyethylaniline,
N-ethyl-N-sulfopropyl-m-)-luidine,
N-ethyl-N-(2-hydroxy-3-sulfopropyl)-m-toluidine, N-ethyl-N-(2-bitroxy-3-sulfopropyl)-m-anisidine, N-ethyl-N-(2 -hydroxy-3-sulfopropyl)aniline, 3,5-dimethoxy-N-ethyl-N-(2-
hydroxy-3-sulfopropyl)aniline, 3.5
-dimethyl-N-ethyl-N-(2-hydroxy-3-
sulfopropyl)aniline, N-ethyl-N-sulfopropyl-m-anisidine, N-ethyl-N-sulfopropyl-3,5-dimethylaniline, N-ethyl-N-sulfopropyl-3,5-dimethoxyaniline, etc. can be mentioned.
またフェノール誘導体の具体例としては、p−クロロフ
ェノール、p−ブロモフェノール、3.5−ジクロロフ
ェニルスルホン酸、3−ヒドロキシ−2,4,6−トリ
ヨード安息香酸等が挙げられる。Specific examples of phenol derivatives include p-chlorophenol, p-bromophenol, 3.5-dichlorophenylsulfonic acid, and 3-hydroxy-2,4,6-triiodobenzoic acid.
更にペンゾチアリノンヒドラゾン誘導体の具体例として
は、3−メチル−2−ベンゾチアゾリノンヒドラゾンが
挙げられる。Furthermore, a specific example of the penzothialinone hydrazone derivative includes 3-methyl-2-benzothiazolinone hydrazone.
アニリン誘導体及びフェノール誘導体の使用濃度に関し
ては特に制限がないが、0.1〜20mM程度が最適で
ある。There are no particular restrictions on the concentrations of the aniline derivatives and phenol derivatives used, but approximately 0.1 to 20 mM is optimal.
4−アミノアンチピリンを用いる場合は、その濃度は1
〜20mMとすることが必要である。これは濃度が1m
M未満であると必要感度が出ない、一方20mMを超え
ると試薬ブランクが大となり、実用性がなくなるからで
ある。またベンゾチアゾリノンヒドラゾン誘導体を用い
る場合は、その濃度を0.1〜2mMとすることが必要
である。これは濃度が0.1 mM未満であると必要感
度が出ない、一方2mMを超えると試薬ブランクが大と
なり、実用性がなくなるからである。When using 4-aminoantipyrine, its concentration is 1
~20mM is required. This has a concentration of 1m
If it is less than M, the required sensitivity will not be achieved, while if it exceeds 20mM, the reagent blank will become large and will be impractical. Further, when using a benzothiazolinone hydrazone derivative, it is necessary to adjust its concentration to 0.1 to 2 mM. This is because if the concentration is less than 0.1 mM, the required sensitivity will not be achieved, while if it exceeds 2 mM, the reagent blank will become large and will be impractical.
本発明方法で用いる試薬はi衝液によってそのpHが調
整されるのであるが、そのpHの値は4.0〜6.0の
範囲とする必要がある。これは最大感度、酵素の至適p
H,呈色安定性に最適であるという理由による。また用
いる緩衝液としては、試薬のpHを4.0〜6.0に設
定できるものであれば何ら限定されるものではないが、
燐酸、酢酸。The pH of the reagent used in the method of the present invention is adjusted using an i buffer, and the pH value must be in the range of 4.0 to 6.0. This is the maximum sensitivity and optimum p of the enzyme.
H. This is because it is optimal for color stability. The buffer to be used is not limited in any way as long as it can set the pH of the reagent to 4.0 to 6.0.
Phosphoric acid, acetic acid.
酒石酸、クエン酸、こはく酸、ジメチルゲルタール酸、
フタル酸、グリシン等の各緩衝液が適当である。そして
これらの緩衝液濃度は、 0.02M〜0.2Mとする
必要がある。これは緩衝液の濃度が0.02M未満であ
ると緩衝液としての機能を達成することができず、又i
1A度がθ、HAを超えると充分な感度が得られないか
らである。tartaric acid, citric acid, succinic acid, dimethyl geltaric acid,
Buffers such as phthalic acid and glycine are suitable. The concentration of these buffer solutions needs to be 0.02M to 0.2M. This is because if the concentration of the buffer solution is less than 0.02M, it cannot function as a buffer solution, and i
This is because if 1A degree exceeds θ, HA, sufficient sensitivity cannot be obtained.
試薬中に含まれる2価鉄の錯イオンについても何ら限定
するものではないが、フェロシアンイオンやフェロセン
イオン等が適当である。しかしながらその濃度について
は正しく調整しなければならず、本発明では1μM以上
とする必要がある。The complex ion of divalent iron contained in the reagent is not limited in any way, but ferrocyan ion, ferrocene ion, etc. are suitable. However, its concentration must be adjusted correctly, and in the present invention, it needs to be 1 μM or more.
これは有効な発色を得る為の必要最小限の濃度である。This is the minimum concentration necessary to obtain effective color development.
試薬は必要によって2種以上に別けて調製してもよいが
、これらを混合して一液状態(使用状態)としたときに
上述の各条件が満足される様に個々の試薬条件を調整す
る必要があるのは言う迄もない。又必要によっては他の
成分、例えば界面活性剤、防腐剤、安定化剤、共存物質
妨害除去剤(リパーゼ、アスコルビン酸オキシダーゼ、
酸化剤等を指す)等を共存させることもできる。更に反
応停止剤(例えばEDTA、アジ化物、フッ化ナトリウ
ム等)を用いることによって、本発明方法をエンドポイ
ント法として利用することも可能である。If necessary, the reagents may be prepared separately into two or more types, but the conditions for each reagent should be adjusted so that each of the above conditions is satisfied when these are mixed to form a single liquid state (state of use). Needless to say, it is necessary. If necessary, other ingredients such as surfactants, preservatives, stabilizers, coexisting substance interference removers (lipase, ascorbic acid oxidase,
(refers to oxidizing agents, etc.) may also be present together. Furthermore, by using a reaction terminator (for example, EDTA, azide, sodium fluoride, etc.), it is also possible to utilize the method of the present invention as an endpoint method.
〔実施例]
以下本発明を実施例によって更に詳細に説明するが、下
記実施例は本発明を限定する性質のものではない。[Examples] The present invention will be explained in more detail below with reference to Examples, but the following Examples are not intended to limit the present invention.
実施例1
被検液中のセルロプラスミン活性を、下記の試薬を用い
下記の方法によって測定した。Example 1 Ceruloplasmin activity in a test solution was measured using the following reagents and the following method.
(試薬)
にH2PO4(PH4,5) ・・・0.0
5M4−アミノアンチピリン(4−AA)・・・4IQ
MN−エチル−N−(2−ヒドロキシ−3−スルホプロ
ピル)−m−Lトルイジン・・・0.4mMフェリシア
ン化カリウム ・・−0,01%トリトンX
−100(商品名) −0,1%(測定方法)
セルロプラスミン含有被検液50μmに、上記試薬を1
、hIL加え37℃で反応させ、その吸光度を波長5
50nmで測定し、その発色速度を求めた。こうして求
められた反応曲線を第1図に、希釈直線性を第2図に夫
々示す。(Reagent) H2PO4 (PH4,5) ...0.0
5M4-aminoantipyrine (4-AA)...4IQ
MN-ethyl-N-(2-hydroxy-3-sulfopropyl)-m-L toluidine...0.4mM potassium ferricyanide...-0,01% Triton X
-100 (Product name) -0.1% (Measurement method) Add 1% of the above reagent to 50 μm of ceruloplasmin-containing test solution.
, hIL was added and reacted at 37°C, and its absorbance was measured at wavelength 5.
The color development rate was determined by measurement at 50 nm. The reaction curve thus determined is shown in FIG. 1, and the dilution linearity is shown in FIG. 2, respectively.
第1図及び第2図の結果からも明らかであるが、本発明
方法に従えば短時間且つ簡単にセルロプラスミンをレー
、トアッセイすることができた。As is clear from the results shown in FIGS. 1 and 2, ceruloplasmin could be rate assayed in a short time and easily according to the method of the present invention.
実施例2
実施例1で示した各種試薬を用い、下記第1表に示す様
に各種の組成条件に設定し、実施例1と同じ測定方法に
よって被検液中のセルロプラスミン活性を測定した。Example 2 Using the various reagents shown in Example 1 and setting various composition conditions as shown in Table 1 below, ceruloplasmin activity in the test liquid was measured by the same measurement method as in Example 1.
その測定結果を下記第2表に示す。The measurement results are shown in Table 2 below.
第 1 表
第 2 表
上記第2表の結果からも明らかであるが、本発明で規定
する全ての要件を満足する組成5は、レートアッセイに
用いる試薬として極めて優れていることが良くわかる。Table 1 Table 2 As is clear from the results in Table 2 above, it is clear that Composition 5, which satisfies all the requirements defined by the present invention, is extremely excellent as a reagent for use in rate assays.
実施例3
被検液中のセルロプラスミン活性を、下記の試薬を用い
て下記の方法によって測定した。Example 3 Ceruloplasmin activity in a test solution was measured by the following method using the following reagents.
(試薬)
K 82 P Oa −K2 HP 04(p H5,
5)・−0,05M4−アミノアンチピリン
・” 4 mM3−ヒドロキシ−2,4,6−
トリヨード安息香酸 ・・・0.5a+
Mフェリシアン化カリウム −0,02%ト
リトンX −100(商品名) −0,1%(
測定方法)
セルロプラスミン含有被検液50μlに上記試薬を1.
0mft加え、37℃で反応させ、その吸光度ヲ波長5
10nmで測定し、その発色速度を求めた。こうして得
られた希釈直線性を第3図に示す。(Reagent) K 82 P Oa -K2 HP 04 (pH 5,
5)・-0,05M4-aminoantipyrine
・"4 mM 3-hydroxy-2,4,6-triiodobenzoic acid...0.5a+
Potassium M ferricyanide -0.02% Triton X -100 (trade name) -0.1% (
Measurement method) Add the above reagent to 50 μl of ceruloplasmin-containing test solution.
Add 0 mft, react at 37°C, and adjust its absorbance to wavelength 5.
The color development rate was determined by measurement at 10 nm. The dilution linearity thus obtained is shown in FIG.
実施例4
被検液中のセルロプラスミン活性を、下記の試薬を用い
下記の方法によって測定した。Example 4 Ceruloplasmin activity in a test solution was measured using the following reagents and the following method.
(試薬)
KH2P 04−に2 HP 04(pH5,5)・・
、0.05M3−メチル−2−ベンゾチアゾリノン
ヒドラゾン 令・−0,5mM
N−エチル−N−(3−スルホプロピル)−m−アニシ
ジン ・・・0.4mMフェリシアン化
カリウム ・・・0.02%トリトンx−to
o (商品名) −0、1%(測定方法)
セルロプラスミン含有被検液50μmに上記試薬1.O
mJZ加え、37℃で反応させ、その吸光度を波長59
0nmで測定し、その発色速度を求めた。(Reagent) KH2P 04-2 HP 04 (pH 5,5)...
, 0.05M 3-methyl-2-benzothiazolinone hydrazone -0.5mM
N-ethyl-N-(3-sulfopropyl)-m-anisidine...0.4mM potassium ferricyanide...0.02% Triton x-to
o (Product name) -0, 1% (Measurement method) Add the above reagent 1. to 50 μm of the test solution containing ceruloplasmin. O
Add mJZ, react at 37°C, and measure the absorbance at wavelength 59.
The color development rate was determined by measurement at 0 nm.
こうして得られた希釈直線性を第4図に示す。The dilution linearity thus obtained is shown in FIG.
[発明の効果]
以上の結果からも明らかであるが、本発明方法に従えば
、セルロプラスミン活性を迅速且つ正確に測定できる様
になフた。[Effects of the Invention] As is clear from the above results, according to the method of the present invention, ceruloplasmin activity could be measured quickly and accurately.
第1図は実施例1におけるセルロプラスミンの反応曲線
を示すグラフ、第2図は実施例1における希釈直線性を
示すグラフ、第3図は実施例3における希釈直線性を示
すグラフ、第4図は実施例4における希釈直線性を示す
グラフである。
第1図
反応時間(分)
ン シ イ イ
希釈系列FIG. 1 is a graph showing the reaction curve of ceruloplasmin in Example 1, FIG. 2 is a graph showing dilution linearity in Example 1, FIG. 3 is a graph showing dilution linearity in Example 3, and FIG. 4 is a graph showing dilution linearity in Example 3. is a graph showing dilution linearity in Example 4. Figure 1 Reaction time (minutes) Dilution series
Claims (1)
ノアンチピリン/フェノール誘導体系、 ベンゾチアゾリノンヒドラゾン誘導体/アニリン誘導体
系 よりなる群から選択されるいずれかの系を用いてセルロ
プラスミン活性を測定するに当たり、pH:4.0〜6
.0 緩衝液の濃度:0.02M〜0.2M 4−アミノアンチピリンの濃度:1〜20mM、ベンゾ
チアゾリノンヒドラゾン誘導体の濃度:0.1〜2mM の各条件を満足する様に調整した反応系中に2価鉄の錯
イオンが1μM以上含まれた状態でセルロプラスミンを
測定することを特徴とするセルロプラスミン活性の測定
方法。[Claims] Ceruloplasmin is produced using any system selected from the group consisting of 4-aminoantipyrine/aniline derivative system, 4-aminoantipyrine/phenol derivative system, and benzothiazolinone hydrazone derivative/aniline derivative system. When measuring activity, pH: 4.0-6
.. 0 Buffer concentration: 0.02M to 0.2M, 4-aminoantipyrine concentration: 1 to 20mM, benzothiazolinone hydrazone derivative concentration: 0.1 to 2mM Reaction system adjusted to satisfy the following conditions. A method for measuring ceruloplasmin activity, comprising measuring ceruloplasmin in a state in which 1 μM or more of divalent iron complex ions are contained.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP8051587A JPH0698025B2 (en) | 1987-03-31 | 1987-03-31 | Method for measuring ceruloplasmin activity |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP8051587A JPH0698025B2 (en) | 1987-03-31 | 1987-03-31 | Method for measuring ceruloplasmin activity |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS63245696A true JPS63245696A (en) | 1988-10-12 |
JPH0698025B2 JPH0698025B2 (en) | 1994-12-07 |
Family
ID=13720451
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP8051587A Expired - Lifetime JPH0698025B2 (en) | 1987-03-31 | 1987-03-31 | Method for measuring ceruloplasmin activity |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH0698025B2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7146202B1 (en) * | 2022-03-11 | 2022-10-04 | 強化土エンジニヤリング株式会社 | Ground grouting material and ground grouting method |
-
1987
- 1987-03-31 JP JP8051587A patent/JPH0698025B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JPH0698025B2 (en) | 1994-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5807696A (en) | Method for determination of cholesterol in low-density lipoprotein | |
CN101120097B (en) | Method, reagent and kit for quantifying cholesterol in remnant-like lipoprotein (RLP) | |
JPH09299A (en) | Determination of cholesterol in lipoprotein fraction having high specific gravity and determination reagent kit | |
JPH042240B2 (en) | ||
CA1203154A (en) | Rapid assaying method for guanase | |
Hynie et al. | Determination of phosphodiesterase I activity in human blood serum | |
JP2619222B2 (en) | Reagents and methods for determining fructosamine content in blood samples or blood-derived samples | |
JP3797603B2 (en) | Method for stabilizing reagent composition | |
JPS63245696A (en) | Method for measuring ceruloplasmin activity | |
JPH07155196A (en) | Method for measuring biological component | |
JP2000189196A (en) | Measurement of urea nitrogen and reagent for measuring urea nitrogen | |
Kamoun et al. | Ultramicromethod for determination of plasma uric acid. | |
US5919644A (en) | Method for assaying sulfate-conjugated bile acid and therefore | |
KR100276749B1 (en) | Method of quantitating cholesterol in low-density lipoprotein | |
EP0702088A1 (en) | Method of determining sodium ion | |
US4722894A (en) | Method for the determination of ceruloplasmin activity | |
JP2805805B2 (en) | Method for measuring superoxide dismutase and reagent for measurement | |
JPS61173799A (en) | Method of determining activity of substrate or enzyme | |
JP3522307B2 (en) | Liquid reagent composition for measuring inorganic phosphorus | |
JPH11243993A (en) | Avoidance of interference of bilirubin on measurement of organismic ingredient | |
EP0464388A1 (en) | Detection assays having chromogenic and nonchromogenic, hypocromogenic, bathochromogenic or hypsochromogenic substrates | |
JP2868553B2 (en) | Method for measuring diaphorase activity | |
JPS5880556A (en) | Chromogen for colorimetry of peroxide | |
JPS60209176A (en) | Method for averting influence of coloration-disturbing material | |
RU1788467C (en) | Method for cholesterine determination |